Evidence map›Paper›PMID 28884432›Full record

ArticleEuropean journal of nutrition2018

Plasma enterolactone and risk of prostate cancer in middle-aged Swedish men.

Peter Wallström, Isabel Drake, Emily Sonestedt, Bo Gullberg, Anders Bjartell, Håkan Olsson, Herman Adlercreutz, Matti J Tikkanen, Elisabet Wirfält

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of nutrition, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Peter WallströmNutrition Epidemiology Research Group, Dept. of Clinical Sciences, Lund University, Malmö, Sweden. peter.wallstrom@med.lu.se.ORCID http://orcid.org/0000-0002-8268-5917
Isabel DrakeClinical Research Centre, Skåne University Hospital, 205 02, Malmö, Sweden.
Emily SonestedtNutrition Epidemiology Research Group, Dept. of Clinical Sciences, Lund University, Malmö, Sweden.
Bo GullbergNutrition Epidemiology Research Group, Dept. of Clinical Sciences, Lund University, Malmö, Sweden.
Anders BjartellDept. of Urology, Lund University, Malmö, Sweden.
Håkan OlssonDept. of Cancer Epidemiology, Lund University, Lund, Sweden.
Herman AdlercreutzFolkhälsan Research Center at University of Helsinki, Haartmaninkatu 8, 00290, Helsinki, Finland.
Matti J TikkanenFolkhälsan Research Center at University of Helsinki, Haartmaninkatu 8, 00290, Helsinki, Finland.
Elisabet WirfältNutrition Epidemiology Research Group, Dept. of Clinical Sciences, Lund University, Malmö, Sweden.
Lund University · SEUniversity of Helsinki · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeEnterolactone (ENL) is formed in the human gut after consumption of lignans, has estrogenic properties, and has been associated with risk of prostate cancer. We examined the association between plasma ENL levels and prostate cancer in a nested case-control study within the population-based Malmö Diet and Cancer cohort. We also examined the association between plasma ENL and dietary and lifestyle factors.

methodsThe study population consisted of 1010 cases occurring during a mean follow-up of 14.6 years, and 1817 controls matched on age and study entry date. We used national registers (95%) and hospital records (5%) to ascertain cases. Diet was estimated by a modified diet history method. Plasma ENL concentrations were determined by a time-resolved fluoroimmunoassay. Odds ratios were calculated by unconditional logistic regression.

resultsThere were no significant associations between plasma ENL and incidence of all prostate cancer (odds ratio 0.99 [95% confidence interval 0.77-1.280] for the highest ENL quintile versus lowest, p for trend 0.66). However, in certain subgroups of men, including men with abdominal obesity (p for interaction = 0.012), we observed associations between high ENL levels and lower odds of high-risk prostate cancer. Plasma ENL was positively associated with consumption of high-fibre bread, fruit, tea, and coffee; with age, and with height, while it was negatively associated with smoking and waist circumference; however, although significant, all associations were rather weak (r ≤ |0.14|).

conclusionENL concentration was not consistently associated with lower prostate cancer risk, although it was weakly associated with a healthy lifestyle.

Indexed as

4-ButyrolactoneCase-Control StudiesHumansLife StyleLignansMaleMiddle AgedProstatic NeoplasmsRisk FactorsSweden2,3-bis(3'-hydroxybenzyl)butyrolactone4-ButyrolactoneLignansDietEnterolactoneLignansNested case–controlProstate cancer

Identifiers

PMID28884432
PMCPMC6182673
OpenAlexW2753207042

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.